BLPH - ベレロフォン・セラピュ―ティクス (Bellerophon Therapeutics Inc.)

BLPHのニュース

   Telemetry Investments L.L.C. Raises Holdings in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)  2021/10/23 14:23:11 Transcript Daily
Telemetry Investments L.L.C. grew its position in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by 48.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 90,920 shares of the biotechnology companys stock after buying an additional 29,878 shares during the period. Telemetry Investments L.L.C. owned []
   Bellerophon Therapeutics (BLPH ) Investor Presentation - Slideshow  2021/09/17 19:57:34 Seeking Alpha
   Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference  2021/09/07 12:30:00 Intrado Digital Media
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23 rd Annual Global Investment Conference, being held September 13-15, 2021.
   Bellerophon Therapeutics EPS beats by $0.25  2021/08/05 13:11:45 Seeking Alpha
   Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results  2021/08/05 12:30:00 Intrado Digital Media
WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021.
   Bellerophon Therapeutics (BLPH ) Investor Presentation - Slideshow  2021/09/17 19:57:34 Seeking Alpha
   Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference  2021/09/07 12:30:00 Intrado Digital Media
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23 rd Annual Global Investment Conference, being held September 13-15, 2021.
   Bellerophon Therapeutics EPS beats by $0.25  2021/08/05 13:11:45 Seeking Alpha
   Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results  2021/08/05 12:30:00 Intrado Digital Media
WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021.
   2 Falling Knives to Catch  2021/07/06 16:46:30 GuruFocus
Athenex and Bellerophon Therapeutics have declined more than 59% over the past 52 weeks Related Stocks: ATNX , BLPH ,
   Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference  2021/09/07 12:30:00 Intrado Digital Media
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23 rd Annual Global Investment Conference, being held September 13-15, 2021.
   Bellerophon Therapeutics EPS beats by $0.25  2021/08/05 13:11:45 Seeking Alpha
   Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results  2021/08/05 12:30:00 Intrado Digital Media
WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021.
   2 Falling Knives to Catch  2021/07/06 16:46:30 GuruFocus
Athenex and Bellerophon Therapeutics have declined more than 59% over the past 52 weeks Related Stocks: ATNX , BLPH ,
   Hedge Funds Are Coming Back To Bellerophon Therapeutics, Inc. (BLPH)  2021/06/29 12:05:00 Insider Monkey

calendar